DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Richard Marais
Richard Marais
ANNUAL REVIEW 1 October 2005–30 September
Cancer Research UK Manchester Institute SCIENTIFIC REPORT 2019
Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Preci
B-RAF Is a Therapeutic Target in Melanoma
Spotlight On
In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling
Cancer Research UK Manchester Institute SCIENTIFIC REPORT 2013
Particulars of Appointment
Newsletter Australia and New Zealand Society for Cell and Developmental Biology INCORPORATED Summer 2015/16 President and President Elect
Targeting the Cyclin-Dependent Kinase 5 in Metastatic Melanoma
Professeur Richard Marais Cancer Research UK – Manchester Institute, Royaume-Uni 45E Prix Fondation ARC Léopold Griffuel De Recherche Translationnelle Et Clinique
Richard Marais CV Short
2018 NCRI Cancer Conference Sunday 4 November – Tuesday 6 November 2018 Programme Details
Rt Hon Boris Johnson MP Prime Minister 10 Downing Street London SW1A 2AA
L597VBRAF Mutant Acts As an Epistatic Modifier of Oncogenic RAS by Enhancing Signaling Through the RAF/MEK/ERK Pathway
Download the Trustees' Report and Financial Statements 2018-2019
Amgen Genentech Merck Celgene
Programme Saturday 4 September 2010
Top View
Pnas11052ackreviewers 5098..5136
Paterson Institute for Cancer Research SCIENTIFIC REPORT 2012
Sunglasses to Hide Behind May Also Prevent Melanoma of the Eyes
Making a Difference to Many
Scientific Report 2018
MRA 2021 Scientific Retreat February 22 – February 24, 2021
Discrepancies Between Uveal and Other Melanomas. a Position Paper from UM Cure 2020
With CUPISCO Slides Removed
In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling
Keynote Speakers
New Insight Puts Craf in Sight As a Therapeutic Target
Ultraviolet Radiation Drives Mutations in a Subset of Mucosal Melanomas
Programme (PDF)
Genetic Screen Finds New Treatment Targets for Lung Cancer 9 July 2013
Paradox-Breaking RAF Inhibitors That Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
The 2Nd Crick International Cancer Conference
Program Chairs Charles Swanton / Michal-Ruth Schweiger - Cologne, DE
Newsletter Autumn 2020